This dissertation aims to determine the prognostic value of pretreatment LAR in advanced NSCLC patients treated with first-line PD-1 checkpoint inhibitors combined with chemotherapy while controlling for other covariates. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.